

From: [Tom Heffernan](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Zachary Decarlotyler](#)
Subject: VT Pharmaceutical Cost Transparency - Biocon Biologics Inc. - Adalimumab Launch Reporting
Date: Friday, May 31, 2024 10:10:03 AM

Some people who received this message don't often get email from theffernan@federalcompliancesolutions.com.
[Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Greetings,

On behalf of Biocon Biologics Inc., and in compliance with House Bill S 92, please find details of Adalimumab's notice of introduction to the market below.

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
Biocon Biologics Inc.	83257-0020-42	Adalimumab fkjp 20 mg/0.4 mL PFS	5/27/2024

Please confirm receipt of this submission and respond with any questions or concerns.

Regards,
Tom Heffernan

Tom Heffernan
Manager

Federal Compliance Solutions LLC
Direct: (484) 767-5327
Email: theffernan@FederalComplianceSolutions.com